Choice of location may boost HIV prevention persistence
NCT ID NCT07335289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether letting people choose where they get their follow-up HIV prevention injections (home, community, or clinic) helps them stick with the treatment. 400 HIV-negative adults in Massachusetts will receive the same-day injectable drug lenacapavir and be randomly assigned to either standard clinic follow-up or a choice of location. The main goal is to see if offering choice improves persistence at 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenacapavir injection
- What this could lead to
- If successful, this could show that offering flexible follow-up locations (home, community, or clinic) helps more people stay on long-acting HIV prevention, making it easier to scale up.
- What could go wrong
- This is an implementation trial, not a test of the drug itself. It is early-stage and small (400 people), so results may not apply broadly. The study hasn't started recruiting yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS USE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital Sexual Health Clinic
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.